Friday, 06 Dec 2019

You are here

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.

Gout patients with a gout flare in the last 12 months were randomly assigned to receive either specially trained, nurse-led care or continue with GP-led usual care. The primary endpoint was the percentage of participants who achieved serum urate concentrations less than 360 μmol/L (6 mg/dL) at 2 years.

A total of 517 gout patients were enrolled, of whom 255 were assigned nurse-led care and 262 usual care. The results were staggeringly in favor of nurse-led care, especially with regard to:

  • Uptake of and adherence to urate-lowering therapy (96% vs 56%, p = 0·0053 )
  • Achieving target urate at 2 years (95% vs 30%, RR 3·18, 95% CI 2·42–4·18, p<0·0001).
  • Fewer flares after 2 years (8% vs 24%;  p <0·0001)
  • The cost per QALY gained for the nurse-led intervention was £5066 at 2 years.

Community-based nurse-led care involving education and engagement of patients and a treat-to-target strategy for urate-lowering therapy achieved target serum urate concentrations and improved patient-centred outcomes in more than 90% of patients with gout.   This study underscores the benefits of educating and engaging patients in gout management and reaffirm the importance of a treat-to-target urate-lowering treatment strategy to improve patient-centred outcomes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.